- Design
- Descriptive observational study of pharmacovigilance queries
- Population
- 2,473 breastfeeding medication queries to the Lyon centre, 2019 to 2023
- Primary outcome
- Recommendation on breastfeeding compatibility
- Effect
- 87% supported continued breastfeeding; 13% unfavourable; 35% involved polytherapy
The Lyon pharmacovigilance centre in France reviewed every breastfeeding medication query it handled from 2019 to 2023: 2,473 requests, about 500 a year. Most came from patients (44%), allied health professionals (29%) or specialists (25%), and two-thirds were postpartum.
In 87% of cases the centre advised that breastfeeding could continue, either without conditions or with monitoring, dose adjustment or timing of doses. Only 13% led to advice to stop either the medicine or breastfeeding, because of formal contraindications, insufficient benefit or too little safety data. Polytherapy, seen in 35%, was associated with more restrictive advice. Chronic disease medicines, such as antihypertensives, antiepileptics and psychotropics, made up 36% of queries. Reported infant adverse effects were rare and non-serious.
This is descriptive and reflects one centre's expert advice rather than measured infant outcomes. But it shows that most queries, when examined, have an answer that allows feeding to continue.
The practical shift is to stop treating breastfeeding as a reason to withhold treatment or to wean by default. In India, where breastfeeding is common and prolonged, that matters for both mother and infant.
- Do not advise stopping breastfeeding by default when a mother needs medication
- Check a dedicated lactation drug reference or a pharmacovigilance service before advising
- Simplify regimens where possible; polytherapy led to more restrictive advice
- Consider timing doses after feeds for drugs with short half-lives
- Plan infant monitoring rather than weaning when data are limited
Why it matters
Mothers are often told to stop breastfeeding when the evidence would have let them continue.
Don't overread it
This describes expert advice from one centre, not a study of infant safety outcomes.
The statistics, in plain English
The 87% reflects expert recommendations in queries sent to one centre, not measured infant outcomes. Infant adverse effects were reported rarely, but passive reporting can miss mild problems.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free